Neuroregeneration Therapy Market Report 2025

The neuroregeneration therapy market size has grown rapidly in recent years. It will grow from $9.98 billion in 2024 to $11.29 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth during the historic period can be attributed to the rising prevalence of neurological disorders, the global increase in the geriatric population, expanding investments in research and development, greater government support and funding, and the growing collaborations between academia and industry.

The neuroregeneration therapy market size is expected to see rapid growth in the next few years. It will grow to $18.23 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to the increasing demand for neuroregeneration therapies, the rising adoption of cell therapies, growing healthcare needs, expanding investments in biotechnology, and the continued rise in the aging population. Key trends expected during this period include advancements in stem cell-based therapies, the development of personalized medicine, innovations in gene editing for neurodegenerative diseases, the application of nanotechnology in drug delivery, and the evolution of pharma-biotech collaborations.

The growing prevalence of neurological disorders is anticipated to drive the expansion of the neuroregeneration therapy market in the coming years. Neurological disorders affect the brain, spinal cord, or peripheral nerves, impairing normal nervous system functions. One of the key contributors to the rise in such conditions is exposure to environmental toxins, as prolonged contact with heavy metals, pesticides, and industrial chemicals can damage the nervous system and increase the risk of neurodegenerative diseases. Neuroregeneration therapy addresses these disorders by repairing or replacing damaged neurons and tissues, restoring lost functions, and promoting healing in the brain, spinal cord, and nerves to improve mobility, sensation, and quality of life. For example, in October 2023, the World Federation of Neurology, a UK-based association of national neurological societies, reported that over 40% of the global population currently suffers from a neurological condition, with this burden projected to nearly double by 2050. Consequently, the increasing prevalence of neurological disorders is fueling the growth of the neuroregeneration therapy market.

The expanding aging population is also expected to accelerate the growth of the neuroregeneration therapy market. An aging population refers to the demographic shift in which the proportion of older individuals in society rises, creating social and healthcare challenges. This growth is driven by longer life expectancy resulting from advancements in healthcare and improved living standards. Neuroregeneration therapy plays a vital role in addressing age-related neurological conditions by repairing damaged nerve cells, enhancing brain function and mobility, and slowing cognitive decline to improve overall quality of life. For instance, in July 2024, the House of Commons Library, a UK-based parliamentary research service, reported that in 2022, individuals aged 65 and over accounted for 19% of the UK’s total population, around 12.7 million people. This figure is projected to rise to 22.1 million, representing 27% of the population, by 2072. As a result, the increasing elderly population is boosting demand for neuroregeneration therapies.

Companies in the neuroregeneration therapy market are also investing in advanced solutions such as resorbable implants to improve peripheral nerve regeneration and patient outcomes. Resorbable implants are medical devices designed to dissolve and be absorbed by the body after serving their purpose, thereby eliminating the need for surgical removal. For example, in March 2022, Integra LifeSciences Holdings Corporation, a US-based biotechnology company, introduced the NeuraGen 3D Nerve Guide Matrix to aid in repairing peripheral nerve discontinuities. The device combines Integra’s bovine type 1 collagen with an innovative inner matrix of porous channels, creating an optimal healing environment by guiding Schwann cell migration and directing axonal growth. This innovation marked a major step forward in peripheral nerve repair, offering surgeons a new solution for short- to mid-gap nerve injuries and representing the result of years of research aimed at improving functional recovery for patients with nerve damage.

Major players in the neuroregeneration therapy market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, Stryker Corporation, Biogen Inc., Synovis Life Technologies Inc., Integra LifeSciences Holdings Corporation, AxoGen Inc., Denali Therapeutics Inc., Aspen Neuroscience Inc., Neurona Therapeutics Inc., Lineage Cell Therapeutics Inc., Checkpoint Surgical Inc., Stemedica Cell Technologies Inc., Polyganics B.V., Epineuron Technologies Inc., NeuExcell Therapeutics Inc.

North America was the largest region in the neuroregeneration therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroregeneration therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neuroregeneration therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Neuroregeneration therapy refers to medical approaches aimed at repairing, regenerating, or replacing damaged neurons and neural tissues in the brain, spinal cord, or peripheral nerves, with the ultimate goal of restoring neurological functions lost due to injury, disease, or degenerative conditions.

The major types of neuroregeneration therapy include stem cell therapy, gene therapy, pharmacological therapy, neurostimulation therapy, and others. Stem cell therapy involves the use of stem cells to repair, replace, or regenerate damaged or diseased cells, tissues, or organs in the body. These therapies employ a range of technologies such as tissue engineering, cranial and spinal stimulation, nanotechnology-based drug delivery, and biomaterials development, and can be administered through various modes including oral, injectable, implantable, and others. Neuroregeneration therapies are applied across multiple indications, including spinal cord injury, traumatic brain injury, stroke, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and peripheral nerve injury. Key end users of these therapies include hospitals, clinical research institutes, academic institutions, and pharmaceutical and biotechnology companies.

The neuroregeneration therapy market research report is one of a series of new reports that provides neuroregeneration therapy market statistics, including the neuroregeneration therapy industry global market size, regional shares, competitors with the neuroregeneration therapy market share, detailed neuroregeneration therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the neuroregeneration therapy industry. This neuroregeneration therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neuroregeneration therapy market consists of revenues earned by entities by providing services such as biomaterial implantation services, surgical interventions for nerve repair, and consulting and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroregeneration therapy market also includes sales of biomaterials, neurostimulation and neuromodulation devices, pharmaceuticals, and neural electrode arrays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.